RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Envisia Therapeutics today announced that it will present data for ENV515, the company’s lead glaucoma product candidate, as well as preliminary data for the company’s novel drug delivery systems designed for the posterior and anterior segments of the eye at the 6th Annual Ocular Diseases and Drug Delivery Conference being held March 20 - 21, 2014 at the Hyatt Regency Mission Bay in San Diego, CA. The Ocular Diseases & Drug Discovery Conference promotes the discovery of ocular disease drug development by bringing together leading scientists, researchers and experts to discuss and collaborate on the latest research and development, safety assessment, regulatory issues and drugs in development for combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, diabetic macular edema (DME), uveitis and other ocular diseases.
Dr. Ben Yerxa, Chief Scientific Officer at Envisia Therapeutics, will present Intraocular Sustained Release PRINT® Implants for the Treatment of Ocular Diseases as part of a session titled Novel Drug Delivery Methods to the Anterior and Posterior Segments, which begins today at 11:20 am PST.
Envisia uses the power of the proprietary PRINT (Particle Replication In Non-Wetting Templates) technology to create particle-based ocular therapeutics that can deliver both small and large molecules in multiple formats.
Envisia’s lead product, ENV515, is an undisclosed marketed prostaglandin analogue that uses a proprietary, fully biodegradable PRINT particle formulation to provide sustained intraocular pressure (IOP) reduction over many months, offering the potential to address the poor compliance that exists today and to limit glaucoma progression and vision loss. Envisia is also exploring how the company’s unique technology can address other important ocular diseases, such as AMD and ocular inflammation.
ABOUT ENVISIA THERAPEUTICS™
Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT technology to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, implantable extended-release formulation of a marketed prostaglandin analogue with the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.